Century Therapeutics

Adrienne Farid, Ph.D., Chief Operating Officer 

Philadelphia, PA 

(NASDAQ: IPSC) 

Virtual Presentation 

Century Therapeutics is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care. 

www.centurytx.com 



By using this website you agree to accept our Privacy Policy and Terms & Conditions